Can a genetic test predict who will benefit from chemo?
NCT ID NCT07587229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to develop a model that uses genetic information from tumor tissue to predict how well gastric cancer patients will respond to chemotherapy. Researchers will analyze RNA splicing patterns and apply machine learning to identify patients who are less likely to benefit from standard treatment. The study involves 329 participants with stage II or III gastric cancer who have already had surgery and received chemotherapy. The goal is to help doctors make more informed treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 329 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with stage II and III gastric cancer who underwent curative resection and received 5-FU-based adjuvant chemotherapy across multiple institutions.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically confirmed stage II or III gastric cancer * Underwent curative surgical resection * Received 5-FU-based adjuvant chemotherapy * Availability of tumor tissue samples for analysis Exclusion Criteria: * History of other malignancies * Inadequate or poor-quality tissue samples (e.g., contamination)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors